Estrogen Use in Protection From Cognitive Decline
This study is designed to assess the effects of estrogen therapy among postmenopausal women at risk for cognitive decline.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Estrogen Use in Protection From Cognitive Decline|
- Changes in cognition and brain metabolism [ Time Frame: Baseline and 24 months ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
whole blood serum urine
|Study Start Date:||August 2003|
|Estimated Study Completion Date:||December 2014|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Continue current hormone therapy
Taper off hormone therapy
A total of 71 postmenopausal women ages 50-65 on estrogen therapy will be randomized to continue or discontinue use of estrogen and will be followed for two years.
Participants will undergo PET and MRI scans and neuropsychological assessments initially and at the end of the two-year follow-up period. These procedures will allow us to evaluate brain metabolism and cognitive performance at baseline and two years following continuation or discontinuation of estrogen therapy.
We hypothesize that women who discontinue estrogen will show more evidence of decline than those who continue estrogen. This project will expand current knowledge of effects of estrogen by 1) determining whether estrogen use among postmenopausal women at risk for cognitive decline is protective of brain metabolism, 2) identifying early predictors for cognitive decline, and 3) developing guidelines for estrogen use in postmenopausal women.
|United States, California|
|Stanford University School of Medicine, Dept. of Psychiatry and Behavioral Sciences|
|Stanford, California, United States, 94070-5723|
|Principal Investigator:||Natalie Rasgon, MD, PhD||Stanford University School of Medicine, Dept of Psychiatry and Behavioral Sciences|
|Principal Investigator:||Terence Ketter, MD||Stanford University|
|Principal Investigator:||Jerome Yesavage, MD||Stanford University|
|Principal Investigator:||Jennifer Hoblyn, MD||VA Palo Alto Health Care System|